CELEZON Tablet

Ruxolitinib (as phosphate)
5 mg
The Arab Pharmaceutical Manufacturing PSC
Pack size 56's Pack
Dispensing mode
Source
Agent
Retail Price 98.05 AED

Indications

CELEZON Tablet is used for: Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-pv) myelofibrosis and post-essential thrombocythemia (post-et) myelofibrosis. [lexicomp] myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue)

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Ruxolitinib (as phosphate) :

Mechanism of Action

Ruxolitinib is a kinase inhibitor that is selective for the janus associated kinases (jak) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (stat) which modulate gene expression. Patients with myelofibrosis have abnormal jak1 and jak2 activity thus ruxolitinib works to regulate this

Note

CELEZON 5 mg Tablet manufactured by The Arab Pharmaceutical Manufacturing PSC. Its generic name is Ruxolitinib (as phosphate). CELEZON is availble in Saudi Arabia. Farmaco SA drug index information on CELEZON Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Ruxolitinib (as phosphate) :